Intellia Therapeutics (NASDAQ:NTLA) Price Target Raised to $91.00 at Chardan Capital

Intellia Therapeutics (NASDAQ:NTLA) had its target price upped by Chardan Capital from $88.00 to $91.00 in a research note issued to investors on Monday morning,Benzinga reports. Chardan Capital currently has a buy rating on the stock.

Other equities analysts have also recently issued research reports about the stock. Oppenheimer reduced their price objective on shares of Intellia Therapeutics from $70.00 to $60.00 and set an “outperform” rating for the company in a research note on Monday, November 11th. Stifel Nicolaus reduced their price objective on shares of Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating for the company in a research note on Wednesday, September 11th. StockNews.com raised shares of Intellia Therapeutics to a “sell” rating in a research note on Friday, November 8th. The Goldman Sachs Group reduced their price objective on shares of Intellia Therapeutics from $31.00 to $20.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. Finally, Evercore ISI raised shares of Intellia Therapeutics to a “strong-buy” rating in a research note on Friday, August 9th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Intellia Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $53.88.

Intellia Therapeutics Trading Up 1.4 %

NTLA opened at $14.17 on Monday. The firm has a 50-day moving average price of $18.64 and a 200-day moving average price of $22.04. Intellia Therapeutics has a twelve month low of $13.54 and a twelve month high of $34.87.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, topping the consensus estimate of ($1.37) by $0.03. The business had revenue of $9.10 million during the quarter, compared to analysts’ expectations of $8.28 million. Intellia Therapeutics’s revenue for the quarter was down 24.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.38) EPS. Equities research analysts anticipate that Intellia Therapeutics will post -5.13 EPS for the current fiscal year.

Insider Transactions at Intellia Therapeutics

In other news, CAO Michael P. Dube sold 2,012 shares of the business’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total value of $38,248.12. Following the completion of the sale, the chief accounting officer now directly owns 47,012 shares in the company, valued at approximately $893,698.12. The trade was a 4.10 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 3.20% of the company’s stock.

Institutional Investors Weigh In On Intellia Therapeutics

A number of hedge funds have recently made changes to their positions in NTLA. Blue Trust Inc. lifted its holdings in shares of Intellia Therapeutics by 1,664.3% in the 2nd quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock worth $33,000 after acquiring an additional 1,398 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Intellia Therapeutics by 763.5% in the second quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock valued at $39,000 after acquiring an additional 1,550 shares during the period. Eastern Bank purchased a new position in shares of Intellia Therapeutics in the third quarter valued at about $41,000. Values First Advisors Inc. bought a new stake in shares of Intellia Therapeutics in the third quarter worth about $54,000. Finally, First Horizon Advisors Inc. increased its position in Intellia Therapeutics by 22.1% during the 2nd quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock valued at $58,000 after purchasing an additional 472 shares during the period. 88.77% of the stock is currently owned by institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.